MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
71.96
-0.88
-1.21%
After Hours: 71.96 0 0.00% 16:34 06/26 EDT
OPEN
72.79
PREV CLOSE
72.84
HIGH
74.74
LOW
69.51
VOLUME
4.85M
TURNOVER
--
52 WEEK HIGH
75.50
52 WEEK LOW
23.65
MARKET CAP
6.35B
P/E (TTM)
-30.7167
1D
5D
1M
3M
1Y
5Y
1D
CG Oncology director Leonard Post disposes of 5,000 common shares worth $350,000
PUBT · 1d ago
CG Oncology 1.15M share Block Trade priced at $66.87
TipRanks · 1d ago
Closing Bell Movers: Micron soars 14% after beat and raise
TipRanks · 2d ago
CG Oncology 1.15M share Block Trade; price range $66.87-$67.87
TipRanks · 2d ago
CG Oncology director Leonard Post disposes of 5,000 shares for $325,000
PUBT · 3d ago
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON), Natera (NTRA) and Pfizer (PFE)
TipRanks · 3d ago
Weekly Report: what happened at CGON last week (0615-0619)?
Weekly Report · 4d ago
Analysts Are Bullish on These Healthcare Stocks: PepGen Inc. (PEPG), CG Oncology, Inc. (CGON)
TipRanks · 5d ago
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.